Please login to the form below

Not currently logged in
Email:
Password:

Civitas appoints Mark Iwicki as CEO

He brings experience gained at Sepracor, Novartis and Merck & Co

Mark Iwicki has joined the Parkinson's focused biopharma Civitas Therapeutics as president and CEO.

Iwicki takes over from the company's co-founder Glenn Batchelder, who will remain on the board of directors.

Tim Nelson, chairman of the board of directors, highlighted Iwicki's previous experience launching products in the pulmonary and central nervous system (CNS) as the company looks to advance its investigational drug CVT-301 for Parkinson's disease.

Nelson said: “Mark's proven ability to lead high performance teams from early development through commercialisation will help achieve the Civitas mission to build a robust and sustainable pipeline around the Arcus platform.”

Arcus is a dry powder and device combination that allows patients to inhale a large, precise dose of medicine regardless of the flow rate of inhalation.

Iwicki said: “It is a great privilege to join the Civitas team during this pivotal period and fully capitalise on the unique capabilities of the Arcus technology.”

Prior to joining Civitas, Iwicki was CEO of Blend Therapeutics having previously served as CEO of Sunovion Pharmaceuticals.

Sunovion was created after the acquisition of Iwicki's former company Sepracor by Dainippon Sumitomo Pharmaceuticals. He was chief commercial officer at Sepracor, launching three products.

Prior to this, he served as senior VP and head of cardiovascular at Novartis. He also has experience at AstraZeneca and Merck & Co.

31st January 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics